Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Metrics to compare | ACXP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipACXPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.0x | −3.4x | −0.5x | |
PEG Ratio | −0.01 | 0.04 | 0.00 | |
Price / Book | 1.5x | 4.0x | 2.6x | |
Price / LTM Sales | - | 7.7x | 3.2x | |
Upside (Analyst Target) | 259.7% | 72.0% | 47.6% | |
Fair Value Upside | Unlock | 3.0% | 6.1% | Unlock |